open access

Vol 17, No 2 (2021)
Case report
Published online: 2020-11-12
Get Citation

Lung ultrasonography in a patient with disseminated melanoma treated with nivolumab

Maria Binkiewicz-Orluk, Marcin Konopka, Edyta Kostarska-Srokosz, Marek Kuch, Wojciech Braksator
DOI: 10.5603/OCP.2020.0039
·
Oncol Clin Pract 2021;17(2):85-88.

open access

Vol 17, No 2 (2021)
CASE REPORT
Published online: 2020-11-12

Abstract

A number of complications after oncological therapy increase with the number of patients who receive the treatment. The diagnostic process might be complicated and requires the use of multimodality imaging to rule out other causes. The immune-related adverse events (irAE) due to nivolumab — as myocarditis and pneumonitis are uncommon but potentially life-threatening. We present a case of a patient who developed both of them in a short-time interval.

Abstract

A number of complications after oncological therapy increase with the number of patients who receive the treatment. The diagnostic process might be complicated and requires the use of multimodality imaging to rule out other causes. The immune-related adverse events (irAE) due to nivolumab — as myocarditis and pneumonitis are uncommon but potentially life-threatening. We present a case of a patient who developed both of them in a short-time interval.

Get Citation

Keywords

lung ultrasonography, melanoma, nivolumab, side effects, pneumonitis, pulmonary toxicity

About this article
Title

Lung ultrasonography in a patient with disseminated melanoma treated with nivolumab

Journal

Oncology in Clinical Practice

Issue

Vol 17, No 2 (2021)

Article type

Case report

Pages

85-88

Published online

2020-11-12

DOI

10.5603/OCP.2020.0039

Bibliographic record

Oncol Clin Pract 2021;17(2):85-88.

Keywords

lung ultrasonography
melanoma
nivolumab
side effects
pneumonitis
pulmonary toxicity

Authors

Maria Binkiewicz-Orluk
Marcin Konopka
Edyta Kostarska-Srokosz
Marek Kuch
Wojciech Braksator

References (6)
  1. Rogiers A, Boekhout A, Schwarze JK, et al. Long-Term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors. J Oncol. 2019; 2019: 5269062.
  2. Brahmer JR, Lacchetti C, Schneider BJ, et al. National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36(17): 1714–1768.
  3. Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016; 2(12): 1607–1616.
  4. Lichtenstein DA. BLUE-protocol and FALLS-protocol: two applications of lung ultrasound in the critically ill. Chest. 2015; 147(6): 1659–1670.
  5. Inglis AJ, Nalos M, Sue KH, et al. Bedside lung ultrasound, mobile radiography and physical examination: a comparative analysis of diagnostic tools in the critically ill. Crit Care Resusc. 2016; 18(2): 124.
  6. Mojoli F, Bouhemad B, Mongodi S, et al. Lung ultrasound for critically III patients. Am J Respir Crit Care Med. 2019; 199(6): 701–714.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl